Research theme for competitive and other funds (3)：
2023 - 2026 Development of a Novel Gene Therapy for Hypophosphatasia
2020 - 2021 Development of gene therapy for hypophosphatasia
2015 - 2019 The gene therapy for hypophosphatasia animal model
Papers (16)：
Tae Matsumoto, Takeshi Yanagihara, Kaoru Yoshizaki, Masami Tsuchiya, Mika Terasaki, Kiyotaka Nagahama, Akira Shimizu, Shinji Kunishima, Miho Maeda. Renal Biopsy-induced Hematoma and Infection in a Patient with Asymptomatic May-Hegglin Anomaly. Journal of Nippon Medical School. 2021. 88. 6. 579-584
Tae Matsumoto, Koichi Miyake, Noriko Miyake, Osamu Iijima, Kumi Adachi, Sonoko Narisawa, José Luis Millán, Hideo Orimo, Takashi Shimada. Treatment with bone maturation and average lifespan of HPP model mice by AAV8-mediated neonatal gene therapy via single muscle injection. Molecular Therapy Methods and Clinical Development. 2021. 12. 22. 330-337
Efficacy and Safety of a Novel Therapeutic Agent (Gene Therapy drug: ARU-2801) for the Treatment of Hypophosphatasia
(The 29th Annual Meeting of Japan Society of Gene and Cell Therapy 2023)
Possibility of prenatal gene therapy for lethal HPP model mice
(2nd Soft Bones 2023)
Efficacy and safety of preclinical gene therapy for hypophosphatasia using ARU-2801 (AAV8 vector expressing TNALP-D10)
(26th American Society of Gene + Cell Therapy 2023)
Development of new gene therapy (ARU-2801 ) for Hypophosphatasia
(2022)
2023/10 - 現在 Nippon Medical School pediatrics department Associate Professor
Association Membership(s) (8)：
関東ジェンダー医療協議会
, GID(性同一性障害)学会
, 食物アレルギー研究会
, JAPANESE SOCIETY OF ALLERGOLOGY
, THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES
, JAPAN PEDIATRIC SOCIETY
, 日本小児内分泌学会
, 日本人類遺伝学会
